SWM
RIGL icon

SVA Wealth Management’s Rigel Pharmaceuticals RIGL Stock Holding History

SVA Wealth Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$35K Hold
1,003
– – ﹤0.01% 228
2020
Q3 		$24K Buy
+1,003
New +$24.6K ﹤0.01% 209

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SVA Wealth Management's RIGL Position: Q4 2020 in Review

SVA Wealth Management held its Rigel Pharmaceuticals (RIGL) position steady in Q4 2020 at 1,003 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #228.

SVA Wealth Management first reported a position in RIGL in Q3 2020 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold RIGL as of Q4 2020.

  • SVA Wealth Management held 1,003 shares of Rigel Pharmaceuticals worth $35K as of Q4 2020.
  • SVA Wealth Management left its Rigel Pharmaceuticals share count unchanged in Q4 2020.
  • Rigel Pharmaceuticals made up ﹤0.01% of SVA Wealth Management's portfolio in Q4 2020, its #228 holding.
  • SVA Wealth Management first reported a position in Rigel Pharmaceuticals in Q3 2020 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2020.

Based on SVA Wealth Management's 13F filing for Q4 2020, filed 4 Feb 2021.